Drug pricing: still a barrier to elimination of HCV - Hallo friend NEWS AN INSPIRATION, In the article you read this time with the title Drug pricing: still a barrier to elimination of HCV, we have prepared well for this article you read and download the information therein. hopefully fill posts Article ECONOMY, Article HEALTH, Article POLITICS, Article SPORTS, Article TRAVELING, Article UPDATE, we write can understand. Well, happy reading.

Titre : Drug pricing: still a barrier to elimination of HCV
link : Drug pricing: still a barrier to elimination of HCV

Drug pricing: still a barrier to elimination of HCV

The Lancet Gastroenterology & Hepatology
Published: December, 2018
DOI: https://doi.org/10.1016/S2468-1253(18)30354-6

Drug pricing: still a barrier to elimination of HCV

On Sept 24, 2018, Gilead announced plans to introduce generic versions of two of their key treatment regimens for chronic hepatitis C virus (HCV) infection—the pangenotypic combination sofosbuvir/velpatasvir (marketed as Epclusa) and sofosbuvir/ledipasvir (Harvoni)—in the USA. The generic versions will be available from January, 2019, via a newly formed subsidiary, Aseguea Therapeutics, and will be listed at US$24 000 for a 12-week course of treatment. Coming at least 10 years before the patents for the originator formulations expire, the prices for the generics represent a substantial reduction in cost compared with launch prices for both originator direct-acting antiviral formulations—initially $74 760 per course for sofosbuvir/velpatasvir and $94 500 for sofosbuvir/ledipasvir. The announcement comes against a backdrop of declining market share, in part due to AbbVie's 2017 launch of the pangenotypic glecaprevir/pibrentasvir regimen at $24 600 for an 8-week course....

Read More: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30354-6/fulltext?dgcid=raven_jbs_etoc_email#.W-RuyC9CAB4.twitter

Thus articles Drug pricing: still a barrier to elimination of HCV

that is all articles Drug pricing: still a barrier to elimination of HCV This time, hopefully can provide benefits to you all. Okay, see you in another article post.

You are now reading the article Drug pricing: still a barrier to elimination of HCV the link address https://newsaninpiration.blogspot.com/2018/11/drug-pricing-still-barrier-to.html

Tweet

Subscribe to receive free email updates: